Gold nanoparticles to improve HIV drug delivery

Future Medicinal Chemistry

Volumn 7, Issue 9, 2015, Pages 1097-1107

  Garrido, Carolina ^a   Simpson, Carrie A ^b   Dahl, Noelle P ^a   Bresee, Jamee ^b   Whitehead, Daniel C ^c   Lindsey, Erick A ^c   Harris, Tyler L ^c   Smith, Candice A ^b   Carter, Carly J ^b   Feldheim, Daniel L ^b   Melander, Christian ^c   Margolis, David M ^a,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD NANOPARTICLE; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG CARRIER; GAG PROTEIN; GOLD; METAL NANOPARTICLE;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TOXICITY; CRYSTAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; SYNTHESIS; TISSUE DISTRIBUTION; ULTRASTRUCTURE; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; BRAIN; DRUG CARRIERS; ENDOTHELIAL CELLS; FEMALE; GOLD; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; RALTEGRAVIR POTASSIUM; TISSUE DISTRIBUTION; VIRUS REPLICATION;

EID: 84935059795     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.57     Document Type: Article

References (41)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131(2), 81-87 (1999).
2. Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Inf. Dis. 49(9), 1441-1449 (2009).
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2007).
4. Mahajan SD, Aalinkeel R, Law WC et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int. J. Nanomedicine 7, 5301-5314 (2012).
5. Nowacek A, Mcmillan J, Miller R, Anderson A, Rabinow B, Gendelman H. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroaids therapeutics. J. Neuroimmune Pharmacol. 5(4), 592-601 (2010).
6. Shibata A, Pham A, Belshan M et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type treatment. AIDS Res. Hum. Retroviruses 29(5), 746-754 (2013).
7. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modifed gold nanoparticles for intracellular gene regulation. Science 312(5776), 1027-1030 (2006).
8. Thaxton CS, Georganopoulou DG, Mirkin CA. Gold nanoparticle probes for the detection of nucleic acid targets. Clin. Chim. Acta 363(1-2), 120-126 (2006).
9. Loo C, Hirsch L, Lee M-H et a l. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt. Lett. 30(9), 1012-1014 (2005).
10. Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc. 129(37), 11653-11661 (2007).
11. Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel pegylated colloidal gold-rh TNF nanomedicine. Clin. Cancer Res. 16(24), 6139-6149 (2010).
12. Bresee J, Maier KE, Melander C, Feldheim DL. Identifcation of antibiotics using small molecule variable ligand display on gold nanoparticles. Chem. Comm. 46, 7516-7518 (2010).
13. Bowman M-C, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130(22), 6896-6897 (2008).
14. Simpson CA, Huffman BJ, Gerdon AE, Cliffel DE. Unexpected toxicity of monolayer protected gold clusters eliminated by PEG-thiol place exchange reactions. Chem. Res. Toxicol. 23(10), 1608-1616 (2010).
15. Simpson CA, Salleng KJ, Cliffel DE, Feldheim DL. In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine 9(2), 257-263 (2013).
16. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662-668 (2006).
17. Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nano 7(1), 62-68 (2012).
18. Tkachenko AG, Xie H, Liu Y et al. Cellular trajectories of peptide-modifed gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15(3), 482-490 (2004).
19. Baumann D, Hofmann D, Nullmeier S et al. Complex encounters: nanoparticles in whole blood and their uptake into different types of white blood cells. Nanomedicine 8(5), 699-713 (2013).
20. Solmaz SR, Chauhan R, Blobel G, Mel ák I. Molecular architecture of the transport channel of the nuclear pore complex. Cell 147(3), 590-602 (2011).
21. Feldherr CM, Lanford RE, Akin D. Signal-mediated nuclear transport in simian virus 40-transformed cells is regulated by large tumor antigen. Proc. Natl Acad. Sci. USA 89(22), 11002-11005 (1992).
22. De La Fuente JM, Berry CC. Tat peptide as an effcient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug. Chem. 16(5), 1176-1180 (2005).
23. Syed S, Zubair A, Frieri M. Immune response to nanomaterials: Implications for medicine and literature review. Curr. Allergy Asthma Rep. 13(1), 50-57 (2013).
24. Bresee J, Bond CM, Worthington RJ et al. Nanoscale structure-activity relationships, mode of action, and biocompatibility of gold nanoparticle antibiotics. J. Am. Chem. Soc. 136(14), 5295-5300 (2014).
25. Ryan JA, Overton KW, Speight ME et al. Cellular uptake of gold nanoparticles passivated with BSA-SV40 large T antigen conjugates. Anal. Chem. 79(23), 9150-9159 (2007).
26. Tkachenko AG, Xie H, Liu Y et al. Cellular trajectories of peptide-modifed gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15(3), 482-490 (2004).
27. Bender AR, Von Briesen H, Kreuter J, Duncan IB, Rübsamen-Waigmann H. Effciency of nanoparticles as a carrier system for antiviral agents in human immunodefciency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40(6), 1467-1471 (1996).
28. Shah L, Amiji M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/aids. Pharm. Res. 23(11), 2638-2645 (2006).
29. Chattopadhyay N, Zastre J, Wong H-L, Wu X, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25(10), 2262-2271 (2008).
30. Shiang Y-C, Ou C-M, Chen S-J et al. Highly effcient inhibition of human immunodefciency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. Nanoscale 5(7), 2756-2764 (2013).
31. Di Gianvincenzo P, Marradi M, Martínez-Ávila OM, Bedoya LM, Alcamí J, Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg. Med. Chem. Lett. 20(9), 2718-2721 (2010).
32. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect. Dis. 13(11), 976-986 (2013).
33. Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HI V-1? Curr. Opin. HIV AIDS 9 (6), 552-558 (2014).
34. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29 (12), 1912-1919 (2008).
35. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf. B Biointerfaces 66(2), 274-280 (2008).
36. Yim YS, Choi JS, Kim GT et al. A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood-brain barrier (bbb). Chem. Commun. (Camb). 48(1), 61-63 (2012).
37. Weiss CK, Kohnle MV, Landfester K et al. The frst step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. ChemMedChem. 3(9), 1395-1403 (2008).
38. Simpson CA, Agrawal AC, Balinski A, Harkness KM, Cliffel DE. Short-chain PEG mixed monolayer protected gold clusters increase clearance and red blood cell counts. ACS nano 5(5), 3577-3584 (2011).
39. De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
40. Rapoport SI, Ohno K, Fredericks WR, Pettigrew KD. Regional cerebrovascular permeability to [14c]sucrose after osmotic opening of the blood-brain barrier. Brain Res. 150 (3), 653-657 (1978).
41. Etame AB, Diaz RJ, O'reilly MA et al. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomedicine 8(7), 1133-1142 (2012).